Hi IronP @IronPig
An excellent point ... “you have to put the cash burn into perspective that previously almost all IMU work was outsourced.”
Yes, a ‘reasonable amount’ of the ‘lead up’ trialing, has been outsourced. This is both common practice and common sense, whenever possible and appropriate. A bio-tech ‘will get more bang for its buck’ this way. The ‘Half-Yearly’ seems solid to me. If you have doubts, just re-read the list of programs in place, and the way they are ‘tracking’. IMU is humming.
Of course, we are still enjoying a ‘free ride’ with some of the programs running ‘in-house’ at City of Hope and much of the new Neo-POLEM trial will be ‘picked-up’ in the UK. There are others of course.
There is now absolutely no way to get around the expenses involved in maintaining the 50-piece orchestra at the azer-cel facility. It has to cut into our budget now, if we are to reap the rewards later. And, I will add, possibly not all that much later. I suspect that the opportunity to supply other ‘cell-players’ in the market, may come sooner than we think. That would provide a nice income stream. Time will tell.
IMU 2.0 is now in play, along with the associated costs. The team continues to ooze confidence in the science. We are only one great announcement away from ‘lift off’. What will it be? As I have suggested several times ... another data-cut in the MAST trial, with ongoing amazing ‘signals’ and continuing positive responses ... and then ...
All the opinion of one poster, of course.
